Patent ID: 9606122
Date: 2017-03-28
CPC Classifications: G01N

Claim:
1. An in vitro method for identifying a human subject having a poor prognosis of 5-year survival of oesophageal and/or gastro-oesophageal junctional (GOJ) adenocarcinoma, the method comprising the steps of: (a) obtaining a tumor tissue sample from said human subject; (b) determining by RT-PCR assay the quantitative expression level of a combination of target genes in said in vitro tumor tissue sample obtained in step (a), wherein the combination of target genes consists of TRIM44, SIRT2, EGFR, and WT1, and the RT-PCR assay utilizes at least one primer selected from the group consisting of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.8; (c) comparing the expression level of each target gene in said combination determined in step (b) with a reference standard for each target gene; (d) detecting an at least 1.3 fold higher level of expression of TRIM44, SIRT2 or EGFR, or an at least 1.3 fold lower level of expression of WT1 as compared with said reference standards in step (c), wherein detecting an at least 1.3 fold higher level of expression of at least one of TRIM44, SIRT2 and EGFR as compared with said reference standards indicates a dysregulated TRIM44, SIRT2 and/or EGFR target gene, and an at least 1.3 fold lower level of expression of WT1 as compared with said reference standard indicates a dysregulated WT1 target gene; and (e) identifying said human subject as having a poor prognosis of 5-year survival of oesophageal and/or GOJ adenocarcinoma based on the dysregulation of at least two of said target genes in said combination consisting of TRIM44, SIRT2, EGFR, and WT1 as detected in step (d).